Pennsylvania
Department of Human Services

Office of Medical Assistance Programs
Bureau of Fee-for-Service Programs, Pharmacy Division
Phone 1-800-537-8862 Fax 1-866-327-0191

DUPIXENT (dupilumab) PRIOR AUTHORIZATION FORM *(form effective 4/10/2026)*

Prior authorization guidelines for **Dupixent** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at https://www.pa.gov/agencies/dhs/resources/for-providers/ma-for-providers/pharmacy-services.

☐New request ☐Renewal request	# of pages: _____	Prescriber name:	
Name of office contact:		Specialty:	
Contact's phone number:		NPI:	State license #:
LTC facility contact/phone:		Street address:	
Beneficiary name:		City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Drug requested: Dupixent	Strength:	Formulation (pen, syringe, etc):	Weight: _____ lbs / kg
Directions:		Quantity:	Refills:
Diagnosis (*submit documentation*):		Diagnosis code (*required*):	
Is Dupixent prescribed by or in consultation with a specialist (e.g., allergist, dermatologist, hematologist/oncologist, immunologist, pulmonologist, rheumatologist, etc.)?		☐Yes ☐No	*Submit documentation of consultation, if applicable.*

Complete the section(s) below applicable to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.

INITIAL requests

1. **For treatment of ASTHMA:** Indicate which of the following apply to the beneficiary. *Check all that apply.*
   - ☐At least ONE of the following:
     - ☐Has a diagnosis of asthma with an eosinophilic phenotype with an absolute blood eosinophil count ≥150 cells/microliter
     - ☐Has a diagnosis of oral corticosteroid-dependent asthma
   - ☐Has asthma that is moderate-to-severe
   - ☐Has tried or cannot use standard asthma controller medications (e.g., inhaled corticosteroids, inhaled long-acting beta agonists [LABAs], etc.)
   - ☐Will use Dupixent in addition to tolerated standard asthma controller medications (e.g., inhaled corticosteroids, inhaled LABAs, etc.)

2. **For treatment of chronic ATOPIC DERMATITIS (AD):** Indicate which of the following apply to the beneficiary. *Check all that apply.*
   - ☐Has at least ONE of the following:
     - ☐A BSA of ≥10% that is affected
     - ☐Involvement of critical areas (e.g., face, feet, genitals, hands, intertriginous areas, scalp)
     - ☐Significant disability or impairment of physical, mental, or psychosocial functioning
   - ☐Tried and failed or cannot try (due to intolerance or contraindication) BOTH of the of the following:
     - ☐ONE of the following:

☐ For the face, skin folds, or other critical areas, a 4-week trial of a low-potency (or higher) topical corticosteroid
☐ For other body areas, a 4-week trial of a medium potency or higher topical corticosteroid
☐ An 8-week trial of a topical calcineurin inhibitor (eg, pimecrolimus, tacrolimus)

3. **For treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD):**
☐ Has COPD that is inadequately controlled on standard COPD controller medications (e.g., inhaled steroids, inhaled LABAs, etc.)
☐ Will use Dupixent as an add-on maintenance treatment
☐ Has a diagnosis of COPD with an eosinophilic phenotype

4. **For treatment of CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (CRSwNP):**
☐ Has CRSwNP that is inadequately controlled on topical intranasal corticosteroids
☐ Will use Dupixent as an add-on maintenance treatment

5. **For treatment of EOSINOPHILIC ESOPHAGITIS (EOE):**
☐ Has tried and failed or cannot try (due to intolerance or contraindication) a proton pump inhibitor (eg, omeprazole, lansoprazole, etc)

6. **For treatment of PRURIGO NODULARIS (PN):**
☐ Has a history of pruritis for at least 6 weeks
☐ Has PN associated with at least ONE of the following:
☐ ≥20 nodular lesions
☐ Significant disability or impairment of physical, mental, or psychosocial functioning

7. **For treatment of BULLOUS PEMPHIGOID:**
☐ Has ONE of the following:
☐ Tried and failed or has a contraindication or an intolerance to systemic corticosteroids
☐ Has corticosteroid-dependent disease
☐ Tried and failed a corticosteroid-sparing therapy (e.g., doxycycline, dapsone, methotrexate, mycophenolate, azathioprine) or has a contraindication or an intolerance to these therapies

8. **For treatment of CHRONIC SPONTANEOUS URTICARIA:** Indicate which of the following apply to the beneficiary. *Check all that apply.*
☐ Remains symptomatic despite H1 antihistamine treatment (e.g., cetirizine, loratadine, etc.)

9. **For treatment of ALLERGIC FUNGAL RHINOSINUSITIS:** Indicate which of the following apply to the beneficiary. *Check all that apply.*
☐ Has a history of sino-nasal surgery

10. **Other diagnosis – specify:** _____

List other treatments tried (including start/stop dates, dose, outcomes, etc.): _____

_____

RENEWAL requests

1. **For the treatment of ASTHMA:**
☐ Has documented measurable evidence of improvement in the beneficiary's asthma
☐ Maintained asthma control while decreasing the oral corticosteroid dose
☐ Is using Dupixent in addition to tolerated standard asthma controller medications (e.g., inhaled corticosteroids, inhaled LABAs, etc.)

2. **For the treatment of ALL OTHER diagnoses:**

Office of Medical Assistance Programs
Bureau of Fee-for-Service Programs, Pharmacy Division
Phone 1-800-537-8862 Fax 1-866-327-0191

☐ Has documented evidence of improvement in disease severity

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	**Date**:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.